Archive | Clinical Trials

Combination Therapies Push Melanoma Field Forward

Combination therapy continues to propel the treatment landscape for patients with melanoma in a positive direction, according to Michael A. Postow, MD, who adds that an area of interest is the combination of BRAF and MEK inhibitors with PD-1 therapy as well as combinations of LAG-3 inhibition plus PD-1 agents.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Ipilimumab Effective in Adolescents With Advanced Melanoma

Ipilimumab (Yervoy) was associated with a 1-year overall survival (OS) rate of 75% in adolescent patients with stage III/IV unresectable malignant melanoma.

Read the full story

Posted in Melanoma In The News, Clinical Trials

IMO-2125, Yervoy Combo is on Fast Track for Treating Refractory Metastatic Melanoma

The U.S. Food and Drug Administration (FDA) granted fast track status to Idera Pharmaceuticals‘ IMO-2125, in combination with Yervoy (ipilimumab), for the treatment of metastatic melanoma patients whose disease progressed after anti-PD-1 therapy.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Combination Therapies Shrink Brain Metastases from Melanoma

Melanoma patients with brain metastases may benefit from two combination regimens used to treat patients who have metastatic melanoma but no brain metastases, according to the early results of ongoing multicenter clinical trials led by investigators from The University of Texas MD Anderson Cancer Center.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories